 Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its lead candidate targeting advanced and metastatic triple-negative breast cancer (TNBC). 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
